hotspot -WSS

hotspot

author：comprehensive 2025-09-02 22:06:19 - browse：7994

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Longer MASH drug regimen improved liver, Akero study finds

WSS

IVF doctors demand details after CooperSurgical lawsuit

Telehealth startups turn to complex chronic diseases

Steward Health Care files for bankruptcy

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Google says AlphaFold 3 can map a vast universe of biomolecules

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

explore

hotspot

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Apple Watch's A

Anesthesiologist group: stop taking Ozempic before surgery

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Microsoft's Peter Lee: Generative AI could help doctors be more human

The high cost of giving birth even with insurance

Bird flu outbreak in cows is latest avian flu curveball

Sports medicine is finally prioritizing gender equality

After gene therapy, two congenitally deaf children hear for the first time

leisure time

Google says AlphaFold 3 can map a vast universe of biomolecules

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

H5N1 bird flu: what we're starting to learn about infection in cows

Researchers on aging grapple with how to calculate biological age

Florida health officials providing scant details on measles cases

The untold story of TV’s first prescription drug ad

knowledge

Wikipedia

leisure time

focus